Explore more publications!

Massachusetts Healthcare Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Healthcare Journal.

Press releases published on September 17, 2025

Parents Forum Brings Free Communication Workshop to Harvard Square Community
Stannah Stairlifts Reaches Trustpilot Milestone, Celebrating 1,000 Customer Reviews
Parents Forum Hosts In-Person Communication Training for Prospective Volunteers
Parents Forum Offers Free Online Workshop for Better Family Communication
OSSIOfiber® Revolutionizes Orthopedic Surgery with Bio-Integrative Implants, Leaving Only Natural Bone Behind
The Choroideremia Research Foundation (CRF) Marks 25 Years of Progress, Research, and Community Support
Northeast Health Services Opens New Mental Health Clinic in Salem, Massachusetts
MtoZ Biolabs Launches PRM Quantitative Proteomics: Empowering Precision in Scientific Research
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Advancing Precision Epigenetic Research: MtoZ Biolabs Characterizes Histone Post-Translational Modifications Using MS
Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
NANOBIOTIX annonce de nouveaux résultats de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients atteints de mélanome cutané résistant aux anti-PD-1
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
CooperCompanies Announces Expanded Share Repurchase Program
Regional Health Properties, Inc. Completes Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares
Vaxart Appoints W. Mark Watson as Lead Independent Director

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions